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Abstract 
RATIONALE The lipid peroxidation product malondialdehyde forms M1dG adducts with guanine 
bases in genomic DNA. The analysis of these adducts is important as a biomarker of lipid 
peroxidation, oxidative stress and inflammation which may be linked to disease risk or exposure 
to a range of chemicals.  
METHODS Genomic DNA samples were subjected to acid hydrolysis to release the adducts in 
the base form (M1G) alongside the other purines. A liquid chromatography-mass spectrometry 
method was optimised for the quantitation of the M1G adducts in genomic DNA samples using 
product ion and multiple reaction mode scans. 
RESULTS Product ion scans revealed four product ions from the precursor ion; m/z 188 → 160, 
133, 106 and 79. The two smallest ions have not been observed previously and optimisation of the 
method revealed that these gave better sensitivity (LOQ m/z 79: 162 adducts per 10
7
 nucleotides; 
m/z 106: 147 adducts per 10
7
 nucleotides) than the other two ions. An MRM method gave similar 
sensitivity but the two smallest product ions gave better accuracy (94-95%). Genomic DNA 
treated with malondialdehyde showed a linear dose-response relationship. 
CONCLUSION A fast reliable sample preparation method was used to release adducts in the base 
form rather than the nucleoside. The methods were optimised to selectively analyse the adducts in 
the presence of other DNA bases without the need for further sample clean-up. Analysis of 
genomic DNA gave results consistent with previous work and was applied to new samples. Thus, 
the method is suitable for the analysis of M1(d)G adducts in biological samples. 
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Introduction 
Malondialdehyde (MDA) is produced in vivo and has been linked to oxidative stress, 
inflammation and lipid peroxidation,
[1, 2]
 and may arise from a number of endogenous or 
exogenous processes. It is known to be mutagenic in bacterial
[3]
 and mammalian cells,
[4]
 and 
enhances DNA damage caused by some chemicals.
[5]
 Lifestyle factors such as smoking,
[6-9]
 high 
fat diets
[2, 10-12]
 and alcohol
[1]
 have been associated with increased MDA levels and there is a vast 
body of evidence that links these to many types of cancer including, but not limited to, lung, 
breast and colorectal cancers.
[13]
 Thus, MDA is widely used as a marker of oxidative stress and 
potential disease risk.
[1, 2]
 Furthermore, MDA is known to form 3-(2-deoxy-β-D-erythro-
pentofuranosyl)pyrimidol[1,2-α]purin-10(3H)-one  (M1dG) adducts with deoxyguanosine in 
DNA.
[14]
 M1dG adducts have been positively associated with smoking,
 [15]
  alcohol.
[10] 
 and diets 
high in saturated fatty acids.
[10, 12], 
. However, there is still ambiguity between studies with 
associations not always being found. For example, Leuratti et al found no association with 
smoking status.
 [15]
 Research has found that M1dG influences the type of mutation that is formed 
depending upon where it is located in the DNA sequence,
[16]
 and that some adducts can be linked 
to mutation hotspots for specific cancers.
[17]
 Thus, M1dG adducts have the potential to lead to 
cancer if repair mechanisms fail to repair either the adduct or the resulting mutation. Hence, it is 
desirable to be able to measure M1dG adduct levels at biological levels in order to investigate the 
effects of exposure and the potential consequences for cancer development, prevention and 
treatment.  
The analysis of M1dG adducts in genomic DNA has been carried out by a number of methods,  
ranging from those involving antibodies and 
32
P-post labelling
[2,  18, 19]
 to coupled mass 
spectrometry methods.
[20, 21]
 However, they all suffer from some disadvantages as well as 
advantages that have been reviewed elsewhere.
[22]
 The main considerations are selectivity and 
sensitivity; techniques employing antibodies or isotope labelling are sensitive but can have 
specificity and reproducibility issues due to the multi-step nature of the methods
[22]
  e.g. 
immunoslot blot assays (1 adduct per 10
8 
nucleotides), 
32
P-post-labelling (1 adduct per 10
10
 
nucleotides) and accelerator mass spectrometry   (1 adduct per 10
12
 nucleotides). These methods 
suffer from loss of structural information although they do have excellent sensitivity. Methods 
using mass spectrometry are widely used and the gold standard for adduct analysis is currently 
high pressure liquid chromatography-tandem mass spectrometry (LC-MS/MS)
[23]
 which is very 
specific due to the combination of separation and mass selection and associated fragmentation 
patterns or reaction monitoring. Furthermore, the instrumentation is starting to approach other 
techniques in sensitivity although larger sample sizes are usually required.
[20]
 Another benefit is 
that the analytes do not need to be labelled for analysis, thus, overcoming issues seen with other 
methods. One of the earliest methods for M1dG analysis was by gas chromatography mass 
spectrometry (GC/MS) which used a acid hydrolysis to release the purines followed by 
derivatisation for volatility.
[20]
 Low recoveries were found and later research has been based on 
LC-MS/MS methods with enzymatic hydrolysis including a recent example
[24]
 and the earlier 
research by Rouzer et al who utilised a LC-MS/MS method to corroborate their data but do not 
appear to have used it for sample analysis.
[20]
 LC-MS/MS has the advantage of not requiring the 
derivatisation step as the adducts are readily analysed in aqueous mobile phases.  At the present 
time, no methods have been published for the direct analysis of the nucleobase, M1G, by LC-
MS/MS without any additional preparation steps e.g. Jeong et al  used an aldehye reactive probe  
derivatisation
[25]
, whilst Ottender et al  employed a reduction of the 6-oxo-M1dG adduct in urine 
samples.
[26]
 In all cases, the mass spectrometry methods were optimised to select the precursor ion 
for the adduct as its nucleoside form and detect product ions based primarily on the constant 
neutral loss (CNL) of the sugar moiety i.e. [MH]
+
 →  [MH – 116 Da]+. This is a common 
approach in adduct analysis with very few examples of analysis of the bases rather than the 
nucleosides. In order to analyse adducts in genomic DNA samples, the initial step is usually to 
release the adducts from the DNA by a lengthy enzymatic hydrolysis to give the nucleosides with 
analysis by CNL as outlined above. In this research, we used a faster acid hydrolysis sample 
preparation method that we have used in other analyses
[18]
 and then optimised the mass 
spectrometry for detection of the adduct as its base form i.e. M1G (pyrimido[1,2-a]purin-10(3H)-
one) rather than M1dG. Harsher acid hydrolysis conditions have been used to release the 
nucleobases prior to derivatisation for GC/MS analysis but not for LC-MS/MS. We previously 
investigated acid hydrolysis conditions for HPLC analysis and found the methodology gave 
accurate data.
 [18]
 Hence, our aim was to utilise the fastest sample preparation methods in 
conjuction with LC-MS/MS analysis of the M1G nucleobase. Monitoring of ions focussed upon 
identifying those specific to M1G, instead of the CNL approach, thus offering greater specificity 
whilst maximising sensitivity. 
Materials and methods 
Materials 
Ammonia solution, formic acid, guanine, iso-propanol, 1,1,3,3-tetramethoxypropane (TMP), 
concentrated hydrochloric acid (HCl), potassium hydroxide (KOH), 100% ethanol, calf thymus 
(CT) DNA, monobasic potassium dihydrogen phosphate (KH2PO4) and Supelclean ENVI-18 
tubes and were purchased from Sigma-Aldrich, Gillingham (UK).  Methanol HiPerSolv and water 
HiPerSolv were from VWR International Ltd, Lutterworth (UK).  
Synthesis of malondialdehyde 
A 100 mM stock solution of MDA was prepared with 0.1664 mL
 
TMP in 4.69 mL HCl (0.1 M) 
and incubated at room temperature for 40 min. The solution was neutralised with 4.69 mL KOH 
(0.1M) and made up to 10 mL with water.
[27]
  
Synthesis and purification of a pyrimido[1,2-a]purin-10(3H)-one standard 
A procedure adapted from Singh et al
[28]
 was used to produce M1G: 0.1 g guanine (0.66 mmoles) 
was dissolved in 10 mL HCl (0.1M) at 40ᵒ C and reacted with 0.326 mL TMP (2 mmoles) for 2 h. 
Upon cooling and filtering, 0.0881 g yellow crystals were acquired (71% crude yield). 
Purification was carried out on SPE Supelclean ENVI-18 Tubes. 10 mg crude M1G was dissolved 
in 1 mL ammonia solution and 9 mL water added. The pH was adjusted with formic acid to ~pH 
5. A SPE cartridge was conditioned with 2 mL methanol followed by 2 mL ammonium formate 
buffer (50 mM, pH 5.4). The crude M1G solution was added to the SPE cartridge and eluted with 
1 mL aliquots of buffer/methanol with increasing methanol in 5% increments from 0–100%. 
250 µL fractions were collected, cooled immediately, and frozen at -20ᵒ C. Fractions with pure 
M1G peaks were identified by HPLC analysis, combined and freeze-dried (0.03 mg). The 
fractions were analysed on a Agilent 1200 series HPLC with PDA (254 nm) and FLD (excitation 
360 nm and emission 500 nm) detectors, Phenomenex Gemini NX 3u C18 110A 100 x 2.00 mm 
column, column temperature 25ᵒ C, mobile phase 25:75 methanol/50 mM ammonium formate 
(pH 5.4), flow rate 0.2 mL/min and 20 µL injection volume. The SPE was repeated as above for 
additional purification. The identity was further confirmed by direct infusion MS and LC-MS in 
positive ion mode (MH
+
 188.2). 
Optimisation of DNA sample preparation and M1G stability 
An acid hydrolysis procedure that has been used previously was optimised for DNA depurination 
and M1G stability.
[18]
 CT-DNA and M1dG-DNA samples were initially analysed for DNA 
concentration by UV with detection at 260 nm. Aliquots were then subjected to ac id hydrolysis 
with formic acid (0.1 M) and incubated for 1 h at 70ᵒ C in a water bath. The samples were dried 
overnight at 40ᵒ C in a centrifugal dryer and redissolved in water, 1 mM formic acid, 100 mM 
formic acid or ammonium formate buffer (50 mM, pH 5.4). Samples were replicated with one set 
being sonicated for 2 mins to aid dissolution. Samples were analysed for guanine by HPLC-UV at 
260 nm and the concentration of DNA calculated. 
The stability of M1G was investigated by subjecting aliquots of the standard to the same acid 
hydrolysis conditions and analysed by HPLC-FLD. Samples were prepared in triplicate. 
Liquid Chromatography-Triple Quadrupole Mass Spectrometry  
Analysis was carried out on a Waters Micromass Quattro Premier Triple Quadrupole Mass 
Spectrometer (Waters, UK), operated by MassLynx v. 4.1 software. Direct infusion of the M1G 
standard was used to determine the optimum collision energy for analysis.  ESI-MS full scan (+ 
ion mode) was measured in the m/z 145 to 300 range with a scan duration of 0.5 s, inter-scan 
delay 0.1 s and a cone voltage 50 V with 10 min data collection. In addition, two low energy 
collision dissociation tandem mass spectrometric analyses (CID-MS/MS) were used: 1) Product 
ion scan of m/z 188 with 28 eV collision energy and 50 V cone voltage; and 2) MRM scan 
monitoring the precursor  product ion transitions at  188 79 m/z and 106 m/z with a 0.05 s 
dwell time. LC separations were carried out on a Waters 2690 HPLC separation module with a 
Waters 996 photodiode array detector (254 nm), Phenomenex Gemini NX 3u C18 110A 100 x 
2.00 mm HPLC column, Phenomenex security guard cartridge guard column and A50-4288 4 mm 
L x 2.00 C18 guard cartridge, column temperature 25ᵒ C mobile phase 25:75 methanol/50 mM 
ammonium formate (pH 5.4), 0.15 mL/min flow rate and 10 µL injection volume. The flow was 
split between the UV and MS in a 2:1 ratio i.e. ~ 0.1 and 0.05 ml/min flow rate to the UV and MS 
respectively. 
Treatment of DNA with malondialdehyde 
CT-DNA was treated with MDA in a modified procedure.
[19]
 50 mg CT-DNA was dissolved in 10 
mL
 
KH2PO4 buffer (0.1 M) with heating at 60ᵒ C. 100 µL DNA aliquots (500 µg) were treated 
with MDA (0 – 50 mM) in a final volume of 500 µL, in triplicate for 5 days in the dark at 37 °C 
in a shaker incubator. The DNA was precipitated by cooling to 4ᵒ C, 500 µL cold iso-propanol 
added and inverted several times, centrifuged for 10 min at 12,000 g and the supernatant removed. 
The DNA pellet was washed with 500 µL cold 100% ethanol and centrifuged at 12,000 g for 10 
min, then 500 µL cold 70% ethanol and centrifuged for 10 min at 12,000 g. The supernatant was 
removed and the DNA pellet used for adduct analysis.  
Sample preparation for adduct analysis 
The precipitated DNA pellets were re-suspended in 500 µL formic acid (0.1 M) and incubated for 
1 h at 70ᵒ C in a water bath. The samples were then dried overnight at 40ᵒ C in a centrifugal dryer 
and stored at -20⁰ C prior to analysis. Samples were warmed to room temperature, dissolved in 
100 µL ammonium formate buffer (50 mM, pH 5.4) and analysed by LC-MS/MS within 24 h. 
Analytical validation criteria 
Specificity 
ESI-MS full scan (+ ion mode), as described above, was carried out on 0.1 mg/mL guanine, 0.1 
mg/mL adenine, M1G standards and a hydrolysed M1dG-DNA standard.
[18]
 A M1G standard (0.5 
µg/mL) was spiked with 10-100 µg of guanine and analysed by LC-MS/MS in all modes.  
Accuracy 
Accuracy was determined by analysis of a M1dG-DNA standard (21 pmol/µg DNA) that had been 
prepared and analysed independently.
[18]
 30 µg M1dG-DNA was hydrolysed in formic acid (500 
µL) as for the extracted DNA pellets and analysed by LC-MS/MS in all modes. 
Precision 
Peak precision was determined by calculating the % relative standard deviation (RSD) for the 
peak with the M1G concentration closest to the limit of quantitation (LOQ). Precision was 
acceptable if < 0.5%.  
Linearity 
A M1G standard (0.1 mg/mL; 535 µM) was prepared in buffer (50 mM ammonium formate, pH 
5.4) with sonication for 20 min. The standard was diluted 10-15,000x in buffer to give standards 
in the range of 0.036 µM- 53.4 µM (7 pg/µL-10 ng/µL). Standard curves of peak intensity versus 
M1G concentration were prepared for each of the product ions and the MRM scan. Correlation 
was assessed across the entire range and within the low range used for sensitivity calculations. 
Limits of detection and quantitation 
The limit of detection (LOD) and LOQ were determined using the calibration line method in the 
range of (0.03-0.5 uM). LOD = 3.3(standard error of regression line/gradient); LOQ = 
10(standard error of regression line/gradient). 
Results and Discussion 
Stability of M1G 
It is known that M1G needs to be kept in neutral or acidic solution during sample preparation and 
analysis procedures. Previous studies have shown that a high pH or the use of tris buffers for 
storage can cause ring-opening.
[29, 30]
 Method development showed that M1G was stable for a few 
days in aqueous solutions and hence standard solutions needed to be prepared daily or kept frozen 
for future use. The measurement of DNA concentration had been previously optimised by 
comparison of UV analysis followed by acid hydrolysis and analysis by HPLC-UV with 
comparable results (3.05 mg/ml and 3.01 mg/ml respectively).
[18]
 During the current optimisation, 
the concentration of DNA samples was verified by UV and HPLC to ensure that the acid 
hydrolysis procedure was effective. It was found that samples must be dried immediately after 
acid hydrolysis to remove all acid and ensure stability of the adduct until analysis. The samples 
were suspended in different solutions with both 10 mM formic acid and the LC buffer giving the 
highest guanine, and hence DNA, concentrations (96% and 97% of the UV concentration 
respectively). Furthermore, sonication of the samples for dissolution of the analyte for HPLC 
analysis gave DNA concentrations that were consistently higher.  Thus samples should be 
suspended in a weak acid buffer (>10 mM formic acid or ammonium formate pH 5.4) with 
sonication immediately prior to analysis. This has proved to be of primary importance in the 
analysis of M1G in DNA samples as the sample must be completely depurinated and then 
redissolved in the LC buffer for reliable results.  
Previous research has shown that HCl (0.01-6 M) is not suitable for acid hydrolysis of M1G due to 
degradation of the adduct and release of pyrimidines. Whereas, , 0.1M formic acid was shown to 
give a higher ratio of M1G adducts than other acids and was stable under the conditions used for 
sample preparation.
[18]
 Furthermore, a CT-DNA sample treated with MDA was then analysed 
using the same acid hydrolysis and HPLC conditions and compared it to data obtained elsewhere 
from a LC/MS analysis and the results were 17pmol/ug DNA and 18pmol/ug DNA 
respectively.
[18]
  The same conditions were used herein and the stability of the adduct was 
verified. Standards subjected to the acid hydrolysis procedure showed no reduction in adduct 
levels after 60 mins compared with the original sample (peak area at t60 = 106% of the t0 
sample). Acid hydrolysis followed by a derivatisation procedure has been used for sample 
preparation for analysis by GC-EC NCI/MS.
[20]
 The stability of M1G in a short oligonucleotide 
duplex was investigated and found to be stable. However, 0.7M formic acid was used confirming 
that the adduct is stable to harsher conditions than used in our studies. Therefore, consideration 
must be given as to whether the adduct is all released or if an under estimation of adducts is 
possible. In previous research the concentration of M1G (and consequently M1dG) was verified 
against independently prepared samples.
[18]
 Thus, the acid hydrolysis procedure appears suitable 
for qunatitation of DNA and M1G concentrations and this research sought to establish conditions 
suitable for LC-MS/MS analysis of the adduct as the base rather than the nucleobase. The ability 
of the current method to provide high quality data is a prime consideration herein. 
Mass Spectrometry Method Development 
Initial ESI-MS (+ ion mode) analysis of the M1G standard by direct infusion showed the optimum 
cone voltage was 50 V that produced the intact protonated adduct of M1G [M1G+H]
+
 at m/z 188. 
At lower cone voltages insufficient ions were generated, whereas higher cone voltages produced 
too much fragmentation with loss of the ions of interest. The optimum collision energy required to 
fragment the precursor ion of M1G into product ions was found to be 28 eV. CID-fragmentation 
resulted in the formation of four product ions at m/z 160, 133, 106 and 79, as shown in Fig. 1. 
This can be explained by a loss of CO (28 Da) to give the largest product ion, and three other 
fragmentations with loss of CO plus multiples of HCN (27 Da) to give the three smaller product 
ions. The major product ion was at m/z 79 which can be explained by a 6-membered ring and is 
expected to be the most stable of the product ions. The two larger product ions have been 
identified by Szekely et al
[31]
 during the analysis of the corresponding nucleoside, M1dG, using 
multi-stage MS/MS analysis. M1dG has an m/z of 304 and neutral loss of the deoxyribose unit 
(116 Da) occurred to give the protonated ion of M1G (m/z 188) which is the starting point of our 
analyses. They then observed the two larger ions seen in our analyses (m/z 160 and 133). 
However, the latter was seen under MS
4
 analysis and explained by fragmentation of the 6-
membered ring rather than the 5-membered ring of the purine moiety as suggested here. It is 
unclear as to whether their proposed fragmentation was confirmed but the ions observed in this 
work are best explained as shown in Fig. 1 with regard to the two additional ions identified. These 
ions were not observed by Szekely et al although their scan range was wide enough had they been 
formed. The difference in the mass spectra can be explained by the fact that their method was 
optimised for the nucleoside, M1dG, and loss of the sugar, whereas our method is optimised to 
ionise and fragment the base, M1G. The majority of published work on adduct analysis by mass 
spectrometry focusses on nucleosides rather than base analysis with the CNL of 116 as the main 
fragmentation as discussed earlier. 
Liquid chromatography-mass spectrometry 
Having established the mass spectrometry conditions, the LC method was optimised. Initially, the 
effect of eluant on the stability of M1G was investigated in a number of acidic solutions as a high 
pH is known to cause ring-opening of the additional ring. This reaction occurs regardless of 
whether the adduct is in the base, nucleoside or nucleotide form so is a problem inherent to all 
analyses. Thus we investigated the use of formic acid, acetic acid and ammonium formate. 
Previous research has utilised ammonium formate in HPLC analyses 
[19]
, and this was also found 
to give the optimum sensitivity under our LC-MS/MS conditions. Isocratic and gradient methods 
were investigated but no advantage was gained in using a gradient method which resulted in 
longer run times due to the re-equilibriation time required. Several flow rates were tested with 
0.15 mL/min being the optimum. Lower flow rates gave better peak separation; however, a 
reduction in sensitivity occurred which was undesirable. A higher flow rate (0.2 mL/min) was 
found to give the greatest sensitivity, but with a reduction in resolution. Thus, the optimum was 
0.15 mL/min which gave better resolution with only a slight loss in sensitivity compared to the 
higher flow rate. 
The mass spectrometry methods were run in conjunction with the optimised LC method. Two 
scans were run by LC-MS/MS, a products of m/z 188 scan and an MRM scan. An initial analysis 
showed that all ions gave good linearity. However, the two product ions of greatest intensity, m/z 
79 and 106, were chosen for optimisation of the method in order to maximise sensitivity. The 
MRM scan was run of two reactions: m/z 188 → 79 and m/z 188 →106. Standards of M1G, 
guanine and adenine were analysed by the optimised LC-MS/MS method. The data obtained for 
M1G is shown in Fig. 2 where M1G eluted at 2.9 min. An additional peak was seen on the UV 
chromatogram at 2.0 min (Fig. 2A) which was also the only peak present when a blank containing 
mobile phase was run, and was absent when water only was run. Fig. 2 shows that this peak was 
not present in any of the MS chromatograms for the standard, and absent in the blank MS 
chromatograms (Fig. 3A). A small peak corresponding to guanine (m/z 152) was detected at 2.3 
min on the product ion TIC chromatogram Fig. 2C, with a relative intensity to the M1G peak of 
0.015% assuming the same response per mass of analyte. This was a problem throughout the 
analysis of M1G using the product ion scan, although the guanine peak did not increase in size 
with increasing M1G concentration. This indicates there may be some degradation of M1G during 
the analysis and was not a standard purity issue. All parameters were optimised to minimise 
analyte degradation but could not be eliminated completely. The guanine peak was not present in 
the MRM scans showing the improved specificity of the methods. Guanine and adenine were 
analysed by all methods to determine if they caused any interference with M1G detection. In 
addition to the product ion and MRM scans, a full scan by LC MS was carried out for all ions 
within the range of m/z 70 – 1000. Guanine eluted at 2.1 min on the full scan chromatogram with 
m/z 151.86 as expected (data not shown). In addition to the product ion and MRM scans, a full 
scan by LC-MS was carried out for all ions within the range of m/z 70 – 1000. Guanine eluted at 
2.1 min on the full scan. However, guanine was not detected by the product ion or the MRM 
scans demonstrating the selectivity of the methods. Adenine was not detected by any of the MS 
modes used but could be seen on the UV chromatogram at 2.7 min (data not shown). This peak 
was quite close to that of M1G; however, as adenine was not detected by MS under these 
conditions, there was not expected to be any interference with M1G detection. Ion suppression is a 
possibility which was not found to be problematic when the accuracy of the method was 
investigated. 
The M1G standard was spiked with different amounts of guanine to determine if there was any 
interference with M1G detection due to signal suppression. Small differences could be seen in the 
peak intensities of the M1G peak between the standards spiked with guanine and those not spiked, 
but not between those spiked with different amounts of guanine. The differences were < ±5% 
from the non-spiked M1G standards and could be attributed to experimental and instrumental 
error. 
A standard curve of M1G was plotted of peak intensity versus M1G concentration for the two 
smallest product ions and MRM, as shown in Fig. 4. All standard curves had good R
2
 values (> 
0.9833), with the MRM showing the best linear fit (0.9955). However, the curve for the smallest 
product ion (m/z 79) showed the steepest gradient. The MRM and m/z 106 curves were very 
similar to one another. 
The sensitivity of the method was calculated by using the calibration line method (Table 1). All 
calibration lines gave R
2 
>0.98 for the standards used.
 
The lowest LOQs gave a %RSD value of 
0.15%, which showed good peak precision. The closest peak on the calibration line to the LOD 
corresponded to 89 nM M1G (167 pg M1G per injection). The MRM and product ion 
chromatograms are shown in Fig. 3 (B). 
The accuracy of the method was assessed by analysis of a M1dG-DNA standard (21 pmol M1G/µg 
DNA) that had been prepared and analysed independently. The chromatograms produced (Fig. 
3C) were all similar to those of the standards. The levels of M1G adduct in the M1dG-DNA 
standard were calculated using the calibration equations of product ions m/z 79 and 106 and the 
MRM scan, as shown in Fig. 4. The injected sample concentrations were ~3 µM which is well 
above the LOQ of the methods. Table 1 shows the data for accuracy obtained by the LC-MS/MS 
methods. The amount of M1G in the M1dG DNA standard was comparable for both product ions 
m/z 79 and 106 with an accuracy of 94-95%. However, the MRM scan gave a much lower amount 
due to reduced ion intensity. The accuracy of both product ion scans is within the acceptable 
range of the previously determined value whereas the MRM analysis is very low despite the 
combined ion intensities of the two MRM acquisitions. However the calibration curve for this 
scan of M1G standard had a lower gradient than the others presumably due to the loss in 
sensitivity associated with MRM mode. These scans were replicated and gave similar results.  
Analysis of M1G Adducts in DNA 
The methods were then applied to CT-DNA that had been treated with MDA to determine if the 
adducts could be quantitated in a more complex matrix comparable to biological samples. The 
same methods were applied and the data processed using the product ions of m/z 79 and 106 as 
these had been found to give the best accuracy. The M1G concentrations are shown in Fig. 5 for 
each MDA concentration used. For both product ions, the concentration of M1G increases with 
the concentration of MDA as expected, although the concentration is slightly lower for m/z 106 
than m/z 79 in every sample. For m/z 79, there was a low concentration (0.16 µM) M1G adducts in 
untreated DNA, which is also often found for many other adducts, however this is below the LOQ 
and just above the LOD, as shown in  Table 1. For m/z 106, the untreated DNA and the DNA 
treated with 0.01 mM MDA have low negative values, which is not expected with samples below 
the LOQ. The levels of M1G detected for the 0.1 mM MDA treatment were below the LOQs, but 
all other MDA concentrations gave adduct levels that were above the LOQ. Thus, levels of M1G 
were not reliable at low concentrations of MDA (≤0.1 mM). However, a clear pattern can be seen 
whereby levels of M1G increased with increasing MDA concentration demonstrating a dose-
response relationship. Treatment with the highest concentration of MDA (50 mM) results in 1.95 
µM and 1.74 µM M1G adducts for m/z 79 and 106 respectively, which corresponds to 
0.39 pmol/µg DNA and 0.35 pmol/µg DNA respectively (1205 adducts per 10
7
 nucleotides and 
1077 adducts per 10
7
 nucleotides). Thus, it appears to be possible to detect an effect from 1 mM 
MDA upwards using a product ion scan which gives a M1G concentration of 367 nM (m/z 79) or 
438 nM (m/z 106)  (227 and 271 adducts per 10
7
 nucleotides respectively). However, the 
sensitivity could be improved by use of the most recent instrumentation where sensitivity can be 
improved by two orders of magnitude.
[32]
 This does appear to be a dose-response relationship, as 
might be expected when treating DNA in solution with MDA and no other interfering factors, 
which suggests that the method would be reliable for measuring adducts in DNA from biological 
samples with appropriate sample clean-up.  
Conclusion 
In conclusion, we have established a reliable method to quantify M1G adducts by LC-MS/MS that 
does not require lengthy expensive enzyme cleavage or derivatisation for the sample preparation 
stage. The method has >94% accuracy, with good precision, linearity and sensitivity in the pg 
range. Most notably, we have identified a fragmentation pattern that appears to be unique to M1G. 
This could therefore be an important contribution to the field of adductomics where unique 
transitions are essential when identifying a range of adducts within biological samples. Precursor-
product ion scans are more suited to adductomics studies than MRM scans as the latter require the 
precursors and products to be known.
[33] 
The methods were applied to CT-DNA samples and 
treatment with MDA resulted in a dose-response relationship as expected. However, only DNA 
was involved and no cellular responses could have repaired these adducts. Future research should 
now focus upon identification of the M1G adducts in biological samples from cells and human 
studies and potential future application to adductomics research.  
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Table 1 The linearity and sensitivity of the M1G standards (30-500 nM) and accuracy of genomic 
DNA analysis by LC-MS/MS 
 
Ion/ 
mode 
LOD LOQ 
R
2
 
Accuracy 
(%) nM adducts/10
7
 nucleotides nM adducts/10
7
 nucleotides 
79 86 53 261 162 0.9923 94.03 
106 78 48 238 147 0.9934 94.59 
MRM 93 57 282 174 0.9587 73.79 
 
  
Figures 
 
 
Figure 1 Proposed fragmentations for the product ions observed for M1G 
  
  
Figure 2 LC-MS/MS chromatograms and mass spectrum of M1G standard (53 µM) - A) UV; 
M1G = 2.96 min , B) MRM; M1G = 2.85 min , C) product ion TIC; guanine = 2.30 min, M1G = 
2.86 min, D) product ion RIC; M1G = 2.86 min, same obtained for m/z 79, 106, 133, 160 and 188  
(E) Mass spectrum of product ion peak at 2.86 min with ions at m/z 79.01, 105.86, 132.85, 159.96 
and 187.89.. The flow is split after the column which accounts for the difference in RT between the 
UV and MS chromatograms. 
  
  
Figure 3 MRM (left) and product ion (right) chromatograms of A) blank, B) M1G standard at 
the LOD (89 nM), C) M1G standard at the LOQ (267 nM), and D) Hydrolysed M1dG-DNA 
standard. The M1G peak elutes at 2.9 min in the MRM and product ion but was not detected in the 
blank.  
  
 
Figure 4 LC-MS/MS calibration curves for M1G standards (0–53 µM) for product ion (m/z 
79 and 106) and MRM (188  79 and 106) analyses. R2 values: 0.9857 (m/z 79), 0.9853 (m/z 
106) and 0.9955 (MRM). 
 
 
  
  
 
Figure 5  M1G concentration in CT-DNA treated with 0 – 50 mM MDA analysed for product 
ions of M1G (m/z 79 and 106). Error bars show ±1 SD from the mean (n = 3). 
 
 
 
